In his role as CEO, Gabe draws on broad experience in both biology and technology to advance Freenome’s mission of giving everyone the tools they need to detect, treat, and ultimately prevent their diseases.
Along with co-founder Riley Ennis, Gabe believes that forging a strong culture is essential to helping Freenome achieve its goals—normalizing mistakes in order to better learn from them, and incorporating core values of empathy, integrity, and trust into every aspect of Freenome’s work.
Gabe holds undergraduate degrees in biology and chemistry from Cornell University. His interest in chromatin biology and the epigenetics of age-associated diseases during graduate studies culminated in the publication of several papers on the application of machine learning to large genomics datasets. In 2014, Gabe founded Acorn, a location-based messaging service, following work as a software engineer at Apple, Glyde, and Tumblr.
With the knowledge and skills he gained as a biotechnology entrepreneur, Riley is helping to make Freenome’s vision of a cancer-free world a reality. As the company’s co-founder and Chief Operating Officer, Riley heads the clinical and commercial development of Freenome’s noninvasive tests for early cancer detection and treatment selection.
A Thiel Fellow, Riley developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. While earning his degree in molecular biology at Dartmouth, Riley co-authored several publications and worked as a visiting scientist with Novartis.
In addition to his work as a scientist, Riley worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of a strong organizational culture firsthand. Riley’s previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.
As Freenome’s Chief Medical Officer and Clinical Laboratory Director, Girish oversees the development and validation of Freenome’s tests and helps navigate the regulatory and reimbursement complexities of the healthcare industry. He continues to serve as a member of CMS’ Medicare Evidence Development & Coverage Advisory Committee.
Previously, Girish was Director of Laboratory Science for Palmetto’s MolDX program, which oversees coverage and reimbursement for molecular testing for over half of the Medicare population. In prior leadership roles at Life Technologies, Ariosa Diagnostics, and Crescendo Bioscience, he oversaw the development, validation, launch, and commercialization of tests in oncology, fetal-maternal health, and rheumatology. In roles at Panorama Capital and RiverVest Venture Partners, Girish focused on life science investments, serving on the boards of several portfolio companies, including Presidio Pharmaceuticals, PowerVision, and Phenomix.
Girish holds an MD, PhD in molecular neuroscience from Washington University in St. Louis, and subspecialized in molecular genetic pathology at Stanford University, where he served as adjunct faculty. He completed undergraduate work at Rice University, and postgraduate studies at the University of London as a Marshall Scholar.
Mike brings over 2 decades of experience to his role as Freenome’s Chief Commercial Officer, building on a proven track record of delivering transformative diagnostic technologies to help clinicians drive better outcomes for their patients. At Freenome, Mike is focused on building a commercial team and making our first early-detection test as broadly accessible to providers and patients as possible.
Mike comes to Freenome from Foundation Medicine, where he served as SVP of Commercial Operations and led a cross-functional team to expand the use of next-generation sequencing technologies in cancer. Experience in past roles at Thermo Fisher, Luminex, Roche Molecular Systems, Roche Diagnostics, and Abbott Diagnostics included general management and commercial leadership of teams and bringing innovative technologies to mainstream utilization in clinical care.
Mike holds a B.S. in Biological Sciences and a MBA from the University of Wyoming.
A clinician by training, Charlie is Freenome’s Chief Partnership Officer, focusing on mid- and longer-term relationships that will help define the company’s future directions and revenues and works closely with the business development team in managing corporate client accounts and institutional collaborations.
Prior to co-founding Freenome, Charlie co-founded a company that uses circulating cell-free (cf)DNA from maternal blood samples to diagnose chromosomal abnormalities during pregnancy. The resulting in-vitro diagnostic, IONA, has been marketed successfully across Europe and the Middle East.
Charlie studied medicine and neuropsychology in the UK, earning a Masters degree from Oxford with a focus on immunotherapy. He has worked in some of the UK’s leading oncology centers, including the Royal Marsden.
In his role as Freenome’s Chief Scientific Officer, Jimmy is responsible for scientific strategy, research operations, and growing the company’s world-class scientific team. He brings a proven record of translating cutting-edge research into commercial success, with a focus on the development and launch of blood-based assays for cancer monitoring and detection of molecular residual disease.
Prior to joining the private sector, as CSO for Oncology at Natera, the global genomic diagnostics company, Dr. Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he spearheaded the computational analyses of the first-ever exome sequencing studies in multiple cancer types.
Dr. Lin holds an MD and a PhD in Cellular and Molecular Medicine from Johns Hopkins School of Medicine, as well as a Master of Health Sciences in Bioinformatics from Johns Hopkins School of Public Health. As an undergraduate at Yale, he majored in Cognitive Science and Molecular Biophysics & Biochemistry. Dr. Lin was a 2016 Senior TED Fellow and is the Founder and President of the Rare Genomics Institute.
In her role leading clinical development, Linda oversees the design and execution of Freenome’s clinical studies used for the development and validation of our tests, including generation of the clinical evidence required for their regulatory approval and reimbursement.
Linda joins Freenome as a seasoned biotech executive, having worked at large, established diagnostic and device companies such as Roche, Becton Dickinson, Celera Diagnostics and Affymetrix, as well as early-stage companies and start-ups, where her roles have spanned leadership positions in clinical and scientific affairs, business development, strategy, innovation, and R&D.
Linda holds an MD, PhD in developmental neurobiology from Stanford, with further clinical training at UCSF, where she served as part-time clinical faculty, treating patients and teaching students. She continues to participate in the UCSF Catalyst program, mentoring faculty who aspire to bring new products to healthcare. Linda completed her undergraduate degree in biochemistry and molecular biology at Caltech.
As head of business development, Blandine is focused on growing and maintaining strategic partnerships with bio-pharmaceutical and academic organizations in the development of the next generation of genomic screening tools and precision oncology therapies.
Before joining Freenome, Blandine was the head of pharma alliance management at Guardant Health, where she oversaw rapid revenue growth, and spent and oversaw product portfolio management at Kraft for more than a decade. In her role as Director of Alliance Management at Alkahest, Blandine cultivated strong relationships with strategic investors and streamlined a framework for strategic financial planning.
Blandine holds an MS in molecular biology from Paris-Sud University and an MS in engineering and management from ISA Engineering and Business School.
IMPACT Advisory Board
With a focus on clinical development, regulatory approval, payer coverage and reimbursement, and health economics, the IMPACT Advisory Board is the cornerstone of Freenome’s commitment to broad patient access to AI-genomic blood tests for the early detection of cancer.
Advisory Board Members
Formerly Commissioner of the US Food and Drug Administration, Dr. Califf is Vice Chancellor for Health Data Science at Duke Health and Director of the Duke University Center for Health Data Science. He has been involved in dozens of landmark clinical trials and is recognized as one of the most-cited medical authors today.
Dr. Grady is a member of the Gastrointestinal Cancer Genetics and Colon Cancer Screening Panel, part of the National Comprehensive Cancer Network, and serves as Professor of Gastroenterology at the University of Washington School of Medicine. His current research centers on novel biomarkers for the prevention and treatment of colon cancer at the Fred Hutchinson Cancer Research Center.
Dr. Hayes is currently the Stuart B Padnos Professor of Breast Cancer Research; and Professor, Internal Medicine, School of Medicine, University of Michigan. Former President of the American Society of Clinical Oncology, he is an authority in the field of breast cancer research with a focus on the identification and validation of tumor biomarker tests.
Dr. Robertson is Chief of Gastroenterology at White River Junction Veterans Affairs Medical Center and Professor at the Geisel School of Medicine at Dartmouth. He has a long standing research interest in colorectal cancer epidemiology and outcomes and currently serves as the Co-Chair of the large CONFIRM trial (N = 50,000 US Veterans). Dr. Robertson is also a member of the US Multi-Society Task Force of Colorectal Cancer.
Formerly Senior Medical Director of Medical Policy, University of Pittsburgh Medical Center (UPMC) Health Plan, Dr. Smalley is a board-certified pathologist advising on payor strategy for coverage and reimbursement, with a focus on the precision medicine applications of next-generation omic technologies. Dr. Smalley is currently Medical Director at AlohaCare and a consulting medical director at UPMC.
Scientific Advisory Board
Comprised of leading experts in genomics and machine learning, the Scientific Advisory Board (SAB) provides strategic and scientific counsel to advance the development of Freenome's technology platform and commercial disease screening products.
Scientific Advisory Board
Dr. Elemento is the Director of the Englander Institute for Precision Medicine. The Institute leverages genomics and artificial intelligence to personalize medicine. Dr. Elemento has led the development of cutting-edge clinical genomics tests that interrogate molecular alterations in disease tissue to match patients with therapy in a highly individualized way. He has published over 200 scientific papers in the area of genomics, epigenomics, computational biology and drug discovery, including in Science and Nature.
Dr. Engelhardt is an Associate Professor in the Computer Science Department at Princeton University, having worked both in both academia and industry. Barbara completed her BS and MS from Stanford University, PhD from UCBerkeley, and postdoc at University of Chicago. She has held positions at Duke University, JPL, Google Research, and 23andMe. Barbara's work centers on the intersection of statistics/machine learning and biomedical data, and she has published in Nature, PNAS and other leading journals, and delivered talks at conferences such as NeurIPS.
Dr. Kundaje is an Assistant Professor of Genetics and Computer Science at Stanford University. His primary research area is large-scale computational regulatory genomics, specializing in developing statistical and machine learning methods for large-scale integrative analysis of heterogeneous, high-throughput functional genomic and genetic data. Anshul was the lead computational analyst of the ENCODE Project and the Roadmap Epigenomics Project and was also a recipient of the 2016 NIH Director's New Innovator Award and the 2014 Alfred Sloan Fellowship.